Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CUVPOSA® safely and effectively. See full prescribing information for CUVPOSA. CUVPOSA (glycopyrrolate) oral solution Initial U.S. Approval: 1961
Medication labelWhy this: Advisory · dailymed-prescription
CUVPOSA is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).
- generic_name
- glycopyrrolate
- product_names
- glycopyrrolate
- ndc
- 0259-0501, 0259-0501-16
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en